AbbVie (ABBV) Falls 13% After Results for Emraclidine in Schizophrenia Did Not Meet their Primary Endpoint

News
1

https://www.streetinsider.com/dr/news.php?id=23955092&gfv=1

AbbVie (NYSE: ABBV) Falls 13% After Results for Emraclidine in Schizophrenia Did Not Meet their Primary EndpointAbbVie (NYSE

Premium-only article. Please sign in or upgrade to SI Premium to view

The crown jewel in AbbVie’s $8.7-billion acquisition of Cerevel Therapeutics failed to live up to expectations in a pair of Phase II studies for schizophrenia, sending the drugmaker’s shares down up to 13% on Monday.

2 Likes
2

This means that we can only hope that Cobenfy is a good medication. We can only hope that Evenamide can be used as monotherapy.

2 Likes
3

https://www.investors.com/news/technology/bristol-myers-squibb-stock-abbvie-stock-schizophrenia-treatment/

4
1 Like